Glucose

Generic Name: Glucose

Brand Names: Bss Ophthalmic Solution, Citrasate, Clinimix 2.75/5, Clinimix E 2.75/5, Dextroject, Dianeal, H.E.L.P.bicel, Hemosate Ultra, Lactate 1-2-3, Leukotrap, Naturalyte, Nauzene, Normosol-R, Nxstage Pureflow, Olimel, Periolimel, Physioneal 40, Sag-M, Sclerodex, Selectbag One

Drug Type: Small Molecule

Unique Ingredient Identifier: IY9XDZ35W2

Background: Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation. It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. Its aldohexose stereoisomer, dextrose or D-glucose, is the most commonly occurring isomer of glucose in nature. L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative. The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation or metabolic disorders where glucose levels are improperly regulated. Glucose is listed on the World Health Organization's List of Essential Medicines.

Indication: Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used in metabolic disorders such as hypoglycemia.

Associated Conditions: Arrhythmia, Caloric Deficit, Edema of the cerebrum, Hypoglycemia, Metabolic Alkalosis

Associated Therapies: Blood Specimen Collection, Electrolyte replacement, Nutritional supplementation, Parenteral Nutrition, Parenteral rehydration therapy, Plasmapheresis, Positive cardiac inotropic effect, Total parenteral nutrition therapy, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

Ultrasound-guided Dextrose Injection Versus Dextrose With Methylprednisolone in Carpal Tunnel Syndrome

Phase 3

Recruiting

Conditions: Carpal Tunnel Syndrome

Interventions: Drug: 5% dextrose injection
Drug: 5% dextrose injections with methylprednisolone acetate 40 mg/ml

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-21

Lead Sponsor: General and Veteran Hospital Croatian Pride Knin

Target Recruit Count: 70

Registration Number: NCT06045013

Locations: 🇭🇷
General and Veteran Hospital "Croatian Pride" Knin, Knin, Croatia

5 Versus 10 Units of Insulin in Hyperkalemia Management

Phase 4

Recruiting

Conditions: Hyperkalemia
Electrolyte Imbalance
Potassium Imbalance
Electrolyte Disturbance

Interventions: Drug: Insulin regular
Drug: Dextrose 50
Drug: salbutamol

First Posted Date: 2023-09-14

Last Posted Date: 2023-10-03

Lead Sponsor: Oman Medical Speciality Board

Target Recruit Count: 336

Registration Number: NCT06036823

Locations: 🇴🇲
Sultan Qaboos University hospital, Seeb, Muscat, Oman

HDP vs NS Intra-articular Injection Among KOA With Obese Patient

Not Applicable

Completed

Conditions: Obesity
Knee Osteoarthritis

Interventions: Drug: Normal Saline
Drug: Dextrose Solution

First Posted Date: 2023-08-01

Last Posted Date: 2023-10-18

Lead Sponsor: Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur, Indonesia

Target Recruit Count: 40

Registration Number: NCT05966948

Locations: 🇮🇩
Rumah Sakit Umum Daerah Haji Provinsi Jawa Timur, Indonesia, Surabaya, East Java, Indonesia

Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection

Phase 3

Not yet recruiting

Conditions: Colorectal Surgery
Post-operative Urinary Retention
Urinary Retention
Rectal Resection
Tamsulosin

Interventions: Drug: pr Sandoz Tamsulosin
Drug: Glucose

First Posted Date: 2023-07-12

Last Posted Date: 2023-07-12

Lead Sponsor: CHU de Quebec-Universite Laval

Target Recruit Count: 220

Registration Number: NCT05941806

Locations: 🇨🇦
Hotel Dieu de Quebec, Québec, Que, Canada
🇨🇦
Hôpital Saint-François d'Assise, Québec, Canada

Dextrose Therapy on Physical Therapy in Subdeltoid Bursitis

Phase 4

Not yet recruiting

Conditions: Subdeltoid Bursitis
Injection
Effect of Drug

Interventions: Drug: Normal saline
Drug: Dextrose

First Posted Date: 2023-06-26

Last Posted Date: 2023-06-27

Lead Sponsor: Taipei Medical University

Target Recruit Count: 46

Registration Number: NCT05918146

Locations: 🇨🇳
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV

Phase 2

Not yet recruiting

Conditions: Acute Respiratory Distress Syndrome
Transesophageal Echocardiography
Right Ventricular Dysfunction

Interventions: Drug: 5% glucose injection
Drug: levosimendan

First Posted Date: 2023-03-14

Last Posted Date: 2023-03-14

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 58

Registration Number: NCT05768230

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects

Phase 1

Completed

Conditions: Obese

Interventions: Drug: Glucose 12 g coated beads (60% w/w)
Drug: Glucose 8 g coated beads (47% w/w)
Drug: Glucose 16 g coated beads (47% w/w)
Drug: Glucose 12 g coated beads (47% w/w)
Drug: Glucose 12 g uncoated beads

First Posted Date: 2023-02-21

Last Posted Date: 2023-02-21

Lead Sponsor: Aphaia Pharma US LLC

Target Recruit Count: 20

Registration Number: NCT05737927

Locations: 🇷🇴
NovaClin Medical Research Center S.R.L, Timisoara, Romania

Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis

Phase 4

Recruiting

Conditions: Peritoneal Dialysis

Interventions: Drug: Icodextrin Peritoneal Dialysis Solution
Drug: Hypertonic Dextrose solution

First Posted Date: 2023-02-10

Last Posted Date: 2024-04-24

Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 194

Registration Number: NCT05721404

Locations: 🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

SODium BICarbonate for Metabolic Acidosis in the ICU

Phase 3

Recruiting

Conditions: Metabolic Acidosis
Shock

Interventions: Drug: 5% Dextrose
Drug: Sodium bicarbonate

First Posted Date: 2023-01-26

Last Posted Date: 2024-06-21

Lead Sponsor: Australian and New Zealand Intensive Care Research Centre

Target Recruit Count: 500

Registration Number: NCT05697770

Locations: 🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇦🇺
Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺
Mater Hospital, South Brisbane, Queensland, Australia

and more 24 locations

The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

Phase 2

Recruiting

Conditions: Mild Cognitive Impairment
Postoperative Cognitive Dysfunction
Postoperative Delirium

Interventions: Drug: Dextrose Water
Drug: Caffeine citrate

First Posted Date: 2022-10-10

Last Posted Date: 2024-03-13

Lead Sponsor: University of Michigan

Target Recruit Count: 250

Registration Number: NCT05574400

Locations: 🇺🇸
Michigan Medicine, Ann Arbor, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy